Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Bullboard Posts
Comment by tuesdaynightridon Oct 15, 2014 9:58pm
140 Views
Post# 23032379

RE:RE:RE:RE:RE:RE:RE:RE:RE:U of Toledo Confirmation Trials

RE:RE:RE:RE:RE:RE:RE:RE:RE:U of Toledo Confirmation TrialsThanks OTC. Despite my poor attempts at humor, I really believe TLT has a unique technology that can effectively eliminate many solid tumors. My main concern is that in poor financial markets, credit will disappear no matter how promising the technology. Therefore, I see it as critical that TLT focus. Per their recent SEDAR update, it now appears that we're at least 9 months away from the ph1/2 trial start up. The only interim catalyst to reinforce the technology is an independent confirmation of the animal data per U of Toledo. As far as Bencro is concerned, he continually regurgitates old information and/or comes up with new, pie in the sky uses for lasers, much of which other suppliers could easily achieve. TLT has a unique laser + PDC combination and that needs to be the focus... the only focus. They have to have the cash 9 months from now to at least begin the trials and that is not a sure thing right now in my mind. I don't expect the recent market sell off lately to be an issue this year but feel that by mid- 2015, we could have a real market sell off. TLT needs to get that trial off the ground with a sense of urgency. The U of T data will provide the only real lift between now and then.
Bullboard Posts